67 related articles for article (PubMed ID: 3516396)
1. Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Schnitzler G; Queisser W; Heim ME; König H; Katz R; Fritze D; Herrmann R; Arnold H; Henss H; Trux FA
Cancer Treat Rep; 1986 Apr; 70(4):477-9. PubMed ID: 3516396
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
Cancer Treat Rep; 1986 Apr; 70(4):481-5. PubMed ID: 3516397
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU.
Villar A; Asensio F; Candel M; Delgado F; Garcia J; Lledó S; Redón J; Roig JV; Sanchez A; Sanchis C
Chemioterapia; 1987 Feb; 6(1):57-62. PubMed ID: 3103932
[TBL] [Abstract][Full Text] [Related]
4. [Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Queisser W; Schnitzler G; Heim ME; König H; Katz R; Fritze D; Herrmann R; Arnold H; Henss H; Trux F
Dtsch Med Wochenschr; 1984 Jun; 109(25):976-80. PubMed ID: 6734453
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
Andersson M; Daugaard S; von der Maase H; Mouridsen HT
Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Levi JA; Fox RM; Tattersall MH; Woods RL; Thomson D; Gill G
J Clin Oncol; 1986 Sep; 4(9):1348-55. PubMed ID: 3528404
[TBL] [Abstract][Full Text] [Related]
8. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
[TBL] [Abstract][Full Text] [Related]
9. Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer.
Hanazaki K; Mochizuki Y; Machida T; Yokoyama S; Sodeyama H; Sode Y; Wakabayashi M; Kawamura N; Miyazaki T
Hepatogastroenterology; 1999; 46(26):1238-43. PubMed ID: 10370699
[TBL] [Abstract][Full Text] [Related]
10. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
[TBL] [Abstract][Full Text] [Related]
12. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy for advanced stomach cancer -- a controlled study of AF and MF].
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2171-8. PubMed ID: 6354100
[TBL] [Abstract][Full Text] [Related]
16. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
19. [The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma].
Weh HJ; Platz D; Garbrecht M; Kremer B; Henne-Bruns D; Crone-Münzebrock W; Hossfeld DK
Dtsch Med Wochenschr; 1989 Sep; 114(37):1391-6. PubMed ID: 2673718
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
